BIT Life Sciences'1st Annual Congress and Expo of Molecular Diagnostics 2008

Welcome to BIT's CEMD-2008
Time: October 22-24, 2008
Venue: Empark Grand Hotel, Beijing, China
Tech tour: October 25-28, 2008; Beijing & Xi' an 

Invitation

Dear Colleagues and Friends,

On behalf of the organizing committee, I cordially welcome you to join the "BIT 1st Annual Congress and Expo of Molecular Diagnostics (CEMD-2008)", which will be held during October 22-24, 2008 in Beijing, China, with a theme of "Accurate and Early Diagnosis of Life-threatening Diseases ".

Molecular diagnostics has been emerging as a field that promises to renew technological progress in the clinical laboratory and vastly improve patient care. It has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike.

This Congress and Expo is organized by BITlifesciences, dedicated to build a platform of the molecular diagnostics industry, as well as to provide insight from key industry leaders concerning cutting-edge molecular diagnostics technology. CEMD-2008 will also provide an integral forum for leaders in trends of MD, in major diseases treatment to share ideas, network with other delegates, deliver new products and advance understanding of the potential of new molecular diagnostics technologies.

CEMD-2008 plans to:
• Invite 10-15 High Profile speakers from leading company of Diagnostics as plenary lecturers
• Integrate 100-150 scientific and technological presentations at the scientific program and workshops
• Organize 150-200 exhibitors and posters to showcase your current work and new products
• Schedule many opportunities for your company’s products introduction with the customers
• Assemble 1000 professionals of clinical laboratory department from the hospitals in China to visit the exhibition

After the scientific program, we will arrange a dream tour to enjoy the scenery of Beijing & Xi' an during October 25-28,2008, such as Great Wall, Summer Palace, Forbidden City and Terra-cotta Soldiers etc. Hope you could enjoy the colorful Chinese immemorial cultures and delicious food at this pleasant season.

We are looking forward to seeing you in Beijing, China.

Helen Zhao
Program Leader
Organizing Committee of the CEMD-2008
26 Gaoneng St., R405
Dalian Hightech Zone
Dalian , LN 116025, China
Tel: 0086-411-84799479
Fax: 0086-411-84799629
Email: helen@bitlifesciences.com

Organizers & SAB

Chair
Hailin Liu (Deputy Director General, China Medicinal Biotech Association, China)

Co-Chair
Ziren Xiao (Deputy Director General, China Medicinal Biotech Association, China)

Executive Chair and Secretary General
Xiaodan Mei (President, Dalian BIT Life Sciences, Inc.)

Deputy Secretary General
Zhaohui Wu (Assistant Secretary General, China Medicinal Biotech Association, China)
Yuefen Chang (Assistant Secretary General, China Medicinal Biotech Association, China)

Membership
Yong Wen (Superior, Membership Department of China Medicinal Biotech Association, China)

Program Leader
Helen Zhao (Director, Dalian BIT Life Sciences, Inc.)

Program Coordinator
Zaylin Zhang (Group Member of Dalian BIT Life Sciences, Inc.)
Vicky Zhu (Group Member of Dalian BIT Life Sciences, Inc.)
Chris Han (Group Member of Dalian BIT Life Sciences, Inc.)

SAB Members
Victor Shi, President of QIAGEN Asia
Julian Burke, CSO and a Main Board Director, Genetix Group plc., UK
Sandeep Gulati, CSO of ViaLogy Corp.
Jan Mous, President and CEO, IntegraGen SA
John Jiang, Principal Scientist, Veridex, LLC, USA
Songming Chen, Research Scientist of Van Andel Research Institute (VARI), USA
Harald Berninge, Director Sales and Marketing, Kreatech Diagnostics, The Netherlands
Caifu Chen, Scientific Fellow, Molecular Cell Biology Division, Sr. Director, Assays R&D, Applied Biosystems, USA
Robert H. Getzenberg, The Donald S. Coffey Professor, Director of Urology Research, Brady Urological Institute
Professor of Urology, Oncology and Pharmacology and Molecular Sciences, Johns Hopkins Hospital, USA
Subhas Chakrabarty, Professor and Associate Dean of Basic Sciences, SIU Cancer Institute., USA
Roberto Sitia, Professor of Cell and Molecular Biology, Vita-Salute University, Italy
Eric Chen, Director, Applied Molecular Profiling Laboratory (AMPL) Toronto, Ontario, Canada
Giuseppe Chiumello, Diretor, University Vita-Salute San Raffaele, Italy
Jennifer A. Byrne, Head, Molecular Oncology, Oncology Research Unit at The Children's Hospital at Westmead, Australia
Karol Sikora, Medical Director of Cancer Partners, UK
Leif Groop, Professor of Department of Clinical Sciences, Diabetes andEndocrinology Research Unit, Lund UniversityDiabetes Centre, Lund University, Sweden
Paul Andrew Checchia, Department of Pediatrics, Division of Critical Care, Washington University School of Medicine, USA
Wei Zhang, Professor and Director of Cancer Genomics Core Laboratory, Texas, USA
Akex Van Belkum, Chairperson of Erasmus MC., The Netherlands
Abdurrahman Coskun, Department of Clinical Biochemistry, Duzce University, School of Medicine, Duzce, Turkey
Chularut Prariyachatigul, Assistant Professor, Department of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand
Li Cai, Director, Molecular Genetics and Molecular Oncology, Laboratory Corporation of America, Center for Molecular Biology and Pathology, USA
Fabrice Fekam Boyom, Department of Biochemistry, Faculty of Science, University of Yaoundé, Cameroon
Berninger, Harald, Director Sales and Marketing, Kreatech Diagnostics, The Netherlands
Michal Daniely, Biology R&D Manager, BioView Ltd., Israel
Shibin Qiu, Senior Scientist, Pathwork Diagnostics Inc
Stephen P. Squinto, Executive Vice President and Head of Research,Alexion Pharmaceuticals Inc, USA
Xiao Zeng, Senior Director, R&D and Business Development, SuperArray, USA
Zhi-Gang Jiang, Program Director, Neurodegenerative Diseases, Panacea Pharmaceuticals, Inc., USA
Joep C. Defesche, Department of Vascular Medicine, Academic Medical Centre at the University of Amsterdam, the Netherlands
Condie E. Carmack, Program Manager, Microarrays, Diagnostics, Life Sciences Solutions Unit, Agilent Technologies, Inc., USA
Qiang Xu, Pricinpal scientitst, Head of Bioinformatics, AltheaDx Inc., USA.
David Perlin, Director and Professor, Public Health Research Institute, UMDNJ-New Jersey Medical School, USA
Ursula Scheefers-Borchel, biochemists and molecular biologists, founder, ScheBo Biotech AG, Germany
Sharif Akhteruzzaman, Professor, Department of Biochemistry and Molecular Biology, University of Dhaka, Bangladesh
Antonius Schuh, Chief Executive Officer , AviaraDx, Inc., USA
Hsian-Rong Tseng, Assistant Professor, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA., USA
Willy A. Valdivia-Granda, CEO, Orion Integrated Biosciences Inc., USA
Joseph Nadeau, Chair/Professor, Department of Genetics, School of Medicine, Case Western Reserve University, USA
T. V. Moorthy, President/CEO, MultiGEN Diagnostics Inc, USA
Raymond Lin, Associate Professor Raymond Lin, Clinical Director, Molecular Diagnosis Centre, National University Hospital , Singapore
Han-Oh Park, President and CEO, Bioneer Corporation, Korea
David W. Moskowit, Chairman, CEO & Chief Medical Officer, GenoMed, Inc., USA
Joel Slomoff, Fulbright & Jaworski L.L.P., Washington, DC., USA
Gyorgy Abel, Director, Department of Laboratory Medicine, Lahey Clinic Medical Center, USA
Ran Nir-Paz, senior physician, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew-University Hospital, Israel
French Blood Agency, Chantal Fournier-Wirth, R&D on Transfusion Transmitted Infectious Diseases, French Blood Establishment, France

Who Should Attend

• Molecular diagnostics companies.
• In vitro diagnostic companies.
• Biotechnology companies.
• Medical devices manufacturers.
• Molecular diagnostic laboratorians.
• Laboratory leaders
• Hospital CFOs and CSOs
• Clinical Laboratories Researcher
• Venture capital firms

Why Attend

• Discover the molecular diagnostics sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success.

• Evaluate the competitive dynamics of the molecular diagnostics market and understand the changing relationship between IVD companies and the molecular diagnostics testing sector.

• Identify the key players in the molecular diagnostics market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players.

• Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users.

• Understand the factors driving growth of the molecular diagnostics market, which represents over 30% of global in vitro diagnostics sales.

Schedule

Full Program

To learn more information about BIT Life Sciences'1st Annual Congress and Expo of Molecular Diagnostics 2008